Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Perihan Dimachkie"'
Publikováno v:
AACE Clinical Case Reports, Vol 3, Iss 4, Pp 353-356 (2017)
ABSTRACT: Objective: This study reports an unusual presentation of autoimmune polyglandular syndrome type II (APS-II) with recurrent cardiac tamponade due to pericarditis in a young male patient.Methods: We report clinical presentation, laboratory da
Externí odkaz:
https://doaj.org/article/8b164d6f8fdf4a14aff2416d3daa0199
Autor:
Muhammad S. Siddiqui, Ildiko Lingvay, Uma Gunasekaran, Laurentiu M. Pop, Katherine Peicher, Ahmed Elhassan, Marconi Abreu, Luigi F. Meneghini, Xilong Li, Beverley Adams-Huet, Olivia Papacostea, Anna Tumyan, Perihan Dimachkie
Publikováno v:
Diabetes, Obesity and Metabolism. 21:2133-2141
Aim To compare the efficacy and safety of a glucagon-like peptide-1 receptor agonist (GLP1RA) plus basal insulin versus basal-bolus insulin treatment in patients with very uncontrolled type 2 diabetes. Materials and methods The SIMPLE study was a 6-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a6e73caf6be01d2780446357ca1f846
https://doi.org/10.1111/dom.13794
https://doi.org/10.1111/dom.13794
Autor:
null Marconi Abreu, null Anna Tumyan, null Ahmed Elhassan, null Katherine Peicher, null Olivia Papacostea, null Perihan Dimachkie, null Muhammad S. Siddiqui, null Laurentiu M. Pop, null Uma Gunasekaran, null Luigi F. Meneghini, null Beverley Adams‐Huet, null Xilong Li, null Ildiko Lingvay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e5fa24f153f99fb980cd4cdd64679b0
https://doi.org/10.1111/dom.13794/v2/response1
https://doi.org/10.1111/dom.13794/v2/response1
Autor:
Muhammad S. Siddiqui, Ahmed Elhassan, Marconi Abreu, Ildiko Lingvay, Olivia Papacostea, Beverley Adams-Huet, Anna Tumyan, Xilong Li, Perihan Dimachkie, Katherine Peicher, Laurentiu M. Pop
Publikováno v:
Diabetes. 67
The SIMPLE study was a randomized trial comparing two treatment strategies [basal insulin (BI) + GLP-1 RA vs. basal-bolus insulin (BBI)] in patients with T2DM and very elevated HbA1c (>10%). The glucose lowering agents were provided free of charge fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58c613018d9b7bc897db0765d7c4a8dc
https://doi.org/10.2337/db18-1077-p
https://doi.org/10.2337/db18-1077-p
Autor:
Anna Tumyan, Ahmed Elhassan, Marconi Abreu, Laurentiu M. Pop, Perihan Dimachkie, Ildiko Lingvay, Xilong Li, Olivia Papacostea, Beverley Adams-Huet, Katherine Peicher, Muhammad S. Siddiqui
Publikováno v:
Diabetes. 67
Basal-bolus insulin (BBI) is the most established treatment strategy for patients with very elevated HbA1c (>10%), especially if symptomatic. The combination of metformin (Met), GLP-1 receptor agonist (GLP-1RA) and basal insulin (BI) is a very effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7234819d2c47ab98fc77dfca68d0caa6
https://doi.org/10.2337/db18-124-or
https://doi.org/10.2337/db18-124-or